All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.
Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccinesPetrecz, Maria et al.Human vaccines & immunotherapeutics. Volume 15:Issue 2 (2019); pp 426-432 -- Landes Bioscience -- Taylor & FrancisOnline access |
2 |
Material Type: Article
|
![]() |
Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccinesPetrecz, Maria et al.Human vaccines & immunotherapeutics. Volume 15:Number 2 (2019, February 1st); pp 426-432 -- Taylor & FrancisOnline access |
3 |
Material Type: Article
|
![]() |
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsStacey, Helen L. et al.Human vaccines & immunotherapeutics. Volume 15:Number 3 (2019, March 4th); pp 530-539 -- Taylor & FrancisOnline access |
4 |
Material Type: Article
|
![]() |
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsStacey, Helen L. et al.Human vaccines & immunotherapeutics. Volume 15:Issue 3 (2019); pp 530-539 -- Landes Bioscience -- Taylor & FrancisOnline access |
5 |
Material Type: Article
|
![]() |
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of ageLi, Xiaoming et al.Vaccine. Volume 33:Issue 12 (2015, March); pp 1499-1505 -- Elsevier ScienceOnline access |